Ann: Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine, page-94

Hamish, I’ll go one step further. The chairman at the helm is actually detrimental to commercialisation opportunities. Not only haven’t we got the right person there to PUT TO BED the deals, we have the chief company representative who might just be driving business elsewhere? I take note that the majority of shareholders ultimately supported the board, and the chairman recently. But at the end of the exercise, and aside from paid Imugene staff, surely the over riding incentive for all shareholders is to see commercial success and huge pay day/s? I understand there are instos in there now making money from loaning and shorting and all the shenanigans, but surely, even they want the big pay day sometime? I think many have failed to realise that Paul Hopper may well be bad for business at the BP commercial level, and it’s taking them a while to cotton on to this sad reality. Time is really ticking now, no more capital raises, no more dilution, no more pay rises and no more acquisitions. Time to deliver the necessary data and DELIVER the commercial success that we have been awaiting for a long time now, and if you can’t do it Paul Hopper, have the good sense to put somebody in place that can. You are very welcome to prove me wrong PH, and I’ll be the first to compliment you if you do.